TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: Identifying a subject as having a propensity to have an adverse cardiovascular event further comprises determining one or more factors consisting of the subject's age, race or ethnic group, sex, body mass index, blood pressure, smoking status, low density lipid (LDL) or high density lipid (HDL) cholesterol level, systolic blood pressure, diastolic blood pressure, history of heart failure, diabetes, renal insufficiency, or left ventricular hypertrophy. The alteration identifies the subject as having an increased propensity to have an adverse cardiovascular event. The adverse cardiovascular event is a fatal or non-fatal myocardial infarction or a stroke. The alteration in the ADD1 gene is ADD1 460Trp polymorphism. The alteration in the beta1-adrenergic receptor gene is the 46G-79C-523C haplotype. The alteration in the beta1-adrenergic receptor gene is the 49S-389R haplotype. The alteration in the beta2-adrenergic receptor gene variants is the 46G-79G-523C haplotype. The alteration in the LTA4H gene variant is the rs2247570 TT or rs1978331 AA. The alteration identifies the subject as having a reduced propensity to have an adverse cardiovascular event. The alteration in the KCNMB1 gene is the Lys65 variant or the Leu110 variant. The alteration in the ALOX5AP gene is the GTC haplotype. Identifying a subject as having an allele variant correlated with increased or decreased efficacy of a treatment comprises analyzing a nucleic acid sample obtained from the subject to determine whether the sample comprises at least one allele variant in a gene consisting of alpha-adducin (ADD1) gene, calcium activated potassium channel (KCNMB1) gene, beta1-adrenergic receptor (ADRB1) gene, beta-2-adrenergic receptor (ADRB2) gene, leukotriene A4 hydrolase (LTA4H), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), CACNA1C, CACNB2 or ALOX5 gene relative to a wild-type reference sequence, the variant being correlated to increased or decreased responsiveness to a treatment for a cardiovascular disorder. The treatment is beta-blocker therapy. The treatment is verapamil SR therapy. The allele variant Lys65 in the calcium activated potassium channel (KCNMB1) gene identifies the subject as responsive to verapamil therapy. The allele variant Leu110 in the calcium activated potassium channel (KCNMB1) gene identifies the subject as responsive to a calcium channel blocker. The absence of the allele variants 46G-79C-523C in the 82-adrenergic receptor gene identifies responsiveness to atenolol therapy. The allele variants 49S-389R in the beta-1-adrenergic receptor gene identifies responsiveness to beta-blocker therapy. The homozygous allele variants AA in the LTA4H gene identify responsiveness to atenolol therapy. The G-allele variant in the LTA4H gene identifies equal responsiveness to verapamil SR or atenolol therapy. The method identifies an allelic variant consisting of a CACNB1 single nucleotide polymorphism (SNP) that is NCBI reference assembly sequence rs1051375 or rs10848683, CACNB2 single nucleotide polymorphism identified by NCB1 Ref Seq: rs120036, an allelic variant in ALOX5, or an allelic variant at Gly 389 of ADRB1. Identifying a cardiovascular therapy for a subject comprises: (a) analyzing a nucleic acid sample obtained from the subject to determine whether the sample comprises at least one allele variant of a gene consisting of alpha-adducin (ADD1) gene, calcium activated potassium channel (KCNMB1) gene, beta1-adrenergic receptor (ADRB1) gene, beta-2-adrenergic receptor (ADRB2) gene, leukotriene A4 hydrolase (LTA4H), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), CACNA1C, CACNB2 or ALOX5 gene, where the variant is correlated to increased or decreased responsiveness to a treatment for a cardiovascular condition; and (b) identifying a treatment regimen for the subject having the allele. The presence of an allele variant Lys65 in the calcium activated potassium channel (KCNMB1) gene identifies verapamil therapy as a treatment regimen for the subject. The presence of allele variant Leu110 in the calcium activated potassium channel (KCNMB1) gene identifies a calcium channel blocker therapy as a treatment regimen for the subject. The presence of allele variants 46G-79C-523C in the beta2-adrenergic receptor identifies verapamil therapy as a treatment regimen for the subject. The absence of the allele variants 46G-79C-523C in the 82-adrenergic receptor gene identifies atenolol therapy as a treatment regimen for the subject. The presence of allele variants 49S-389R in the beta1-adrenergic receptor gene identifies beta-blocker therapy as a treatment regimen for the subject. The presence of homozygous allele variants AA in the LTA4H gene identifies atenolol therapy as a treatment regimen for the subject. The G-allele variant in the LTA4H gene identifies verapamil SR or atenolol therapy as a treatment regimen for the subject. The method further comprises determining one or more factors consisting of the subject's age, race or ethnic group, sex, body mass index, blood pressure, smoking status, low density lipid (LDL) or high density lipid (HDL) cholesterol level, systolic blood pressure, diastolic blood pressure, history of heart failure, diabetes, renal insufficiency, or left ventricular hypertrophy. Identifying a subject in need of early and aggressive cardiovascular therapy comprises analyzing a nucleic acid sample in a gene consisting of alpha-adducin (ADD1) gene, calcium activated potassium channel (KCNMB1) gene, beta1-adrenergic receptor (ADRB1) gene, beta-2-adrenergic receptor (ADRB2) gene, leukotriene A4 hydrolase (LTA4H), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), CACNA1C, CACNB2 or ALOX5 gene obtained from the subject to determine whether the sample comprises at least one allele variant correlated to a propensity to have an adverse cardiovascular event, thereby identifying a treatment regiment for the subject. The method further comprises determining one or more factors consisting of the subject's age, race or ethnic group, sex, body mass index, blood pressure, smoking status, low density lipid (LDL) or high density lipid (HDL) cholesterol level, systolic blood pressure, diastolic blood pressure, history of heart failure, diabetes, renal insufficiency, or left ventricular hypertrophy. Determining a subject's propensity for an adverse cardiovascular event comprises: (a) determining, in a sample from the subject, the presence or absence of an allelic variant in a gene consisting of alpha-adducin (ADD1) gene, calcium activated potassium channel (KCNMB1) gene, beta1-adrenergic receptor (ADRB1) gene, beta-2-adrenergic receptor (ADRB2) gene, leukotriene A4 hydrolase (LTA4H), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), CACNA1C, CACNB2 or ALOX5 gene; (b) assessing age, race, sex, body mass index, blood pressure, smoking status, low density lipid (LDL) or high density lipid (HDL) cholesterol level, systolic blood pressure, diastolic blood pressure, history of heart failure, diabetes, renal insufficiency, or left ventricular hypertrophy, alcohol consumption history, smoking history, exercise history, diet or family history of cardiovascular disease; and (c) correlating the presence of the allele variant and one or more cardiovascular disease risk factors with the need for early and aggressive cardiovascular therapy, where a positive correlation identifies the subject as having a propensity for an adverse cardiovascular event. The method further comprises selecting an appropriate treatment regimen. The method further comprises administering the treatment regimen to the subject. Identifying a subject as in need of prophylactic cardiovascular therapy comprises: (a) determining, in a sample from the subject, the presence or absence of an allelic variant in a gene consisting of alpha-adducin (ADD1) gene, calcium activated potassium channel (KCNMB1) gene, beta1-adrenergic receptor (ADRB1) gene, beta-2-adrenergic receptor (ADRB2) gene, leukotriene A4 hydrolase (LTA4H), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), CACNA1C, CACNB2 or ALOX5 gene; (b) assessing age, race, sex, body mass index, blood pressure, smoking status, low density lipid (LDL) or high density lipid (HDL) cholesterol level, systolic blood pressure, diastolic blood pressure, history of heart failure, diabetes, renal insufficiency, or left ventricular hypertrophy, alcohol consumption history, smoking history, exercise history, diet, and family history of cardiovascular disease; and (c) correlating the presence of the allele variant and one or more cardiovascular disease risk factors with the need for prophylactic cardiovascular therapy. The sample is an oral tissue sample or biological fluid sample. The biological fluid sample is saliva, urine or blood. The oral sample is a buccal swab, scraping or wash. The presence or absence of the allele variant is identified by amplifying or failing to amplify an amplification product from the sample. The amplification product is digested with a restriction enzyme before analysis. The presence or absence of the allele variant is identified by hybridizing the nucleic acid sample with an oligonucleotide primer labeled with a detectable moiety. The method further comprises reporting the identification to the subject. The detectable moiety is detected in an enzymatic assay, radioassay, immunoassay, or by detecting fluorescence. The detectable moiety is SYBR Green I, YOPRO-1, thiazole orange, Hex, pico green, edans, fluorescein, FAM or TET. The primers for amplification are located on a chip. The primers for amplification are specific for alleles of the genes. The method further comprises reporting a result to a healthcare provider. Selecting a cardiovascular therapy for a subject comprises identifying a subject as having an allelic variant in CACNAIC. The allelic variant is a SNP identified by NCBI Ref Seq rs10848683 or rs1051375. The method comprises identifying a subject as having an allelic variant in CACNB2. The method identifies the presence of a single nucleotide polymorphism identified by NCBI Ref Seq: rs120036. The method comprises identifying a subject as having an allelic variant in ALOX5. The allelic variant is a tandem repeat promoter polymorphism. The therapy selected is beta blocker therapy. The beta blocker therapy is an effective amount of atenolol. The test results are reported to a subject or to a health provider. The test results are used to select a method of treatment. Preferred Microarray: The nucleic acid microarray comprises a nucleic acid molecule comprising at least a fragment of two or more genes alpha-adducin (ADD1) gene, calcium activated potassium channel (KCNMB1) gene, beta1-adrenergic receptor (ADRB1) gene, beta-2-adrenergic receptor (ADRB2) gene, leukotriene A4 hydrolase (LTA4H), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), CACNA1C, CACNB2 or ALOX5 gene. The nucleic acid sequences comprise sequences for at least two different alleles for each of the genes. Preferred Set: The primer set comprises primers that bind to two or more genes consisting of alpha-adducin (ADD1) gene, calcium activated potassium channel (KCNMB1) gene, beta1-adrenergic receptor (ADRB1) gene, beta-2-adrenergic receptor (ADRB2) gene, leukotriene A4 hydrolase (LTA4H), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), CACNA1C, CACNB2 or ALOX5 gene. At least one primer binds differentially to two different alleles of one of the genes. The primer is labeled with a detectable moiety. The detectable moiety is detected in an enzymatic assay, radioassay, immunoassay, or by detecting fluorescence. The detectable moiety is SYBR Green I, YOPRO-I, thiazole orange, Hex, pico green, edans, fluorescein, FAM, or TET. Preferred Kit: The kit for determining the presence or absence of an allelic variant in a biological sample from a subject comprises a nucleic acid sequence that hybridizes to a gene consisting of alpha-adducin (ADD1) gene, calcium activated potassium channel (KCNMB1) gene, beta1-adrenergic receptor (ADRB1) gene, beta-2-adrenergic receptor (ADRB2) gene, leukotriene A4 hydrolase (LTA4H), arachidonate 5-lipoxygenase-activating protein (ALOX5AP), CACNA1C, CACNB2 or ALOX5 gene. Preferred Representation: The representation of the test results of any one of the methods above is present on a computer screen or a physical medium. The physical medium is paper. The representation further comprises information relating to selection of a treatment or prophylactic method. Preferred Composition: The pharmaceutical composition comprises a therapeutic agent labeled for use in a patient. The therapeutic agent is a beta blocker. EXAMPLE - No suitable example given.